US Patents With Foreign Priority to India Patent: 2596/CHE/2014

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use
Tg Theraps	UKONIQ	umbralisib tosylate	TABLET;ORAL	213176-001	Feb 5, 2021		DISCN	Yes	No	10,414,773		Y	Y		RELAPSED OR REFRACTORY MARGINAL ZONE LYMPHOMA (MZL) WHO HAVE RECEIVED AT LEAST ONE PRIOR ANTI-CD20-BASED REGIMEN
Tg Theraps	UKONIQ	umbralisib tosylate	TABLET;ORAL	213176-001	Feb 5, 2021		DISCN	Yes	No	10,414,773		Y	Y		RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA (FL) WHO HAVE RECEIVED AT LEAST THREE PRIOR LINES OF SYSTEMIC THERAPY
Tg Theraps	UKONIQ	umbralisib tosylate	TABLET;ORAL	213176-001	Feb 5, 2021		DISCN	Yes	No	10,947,244					RELAPSED OR REFRACTORY MARGINAL ZONE LYMPHOMA (MZL) WHO HAVE RECEIVED AT LEAST ONE PRIOR ANTI-CD20-BASED REGIMEN
Tg Theraps	UKONIQ	umbralisib tosylate	TABLET;ORAL	213176-001	Feb 5, 2021		DISCN	Yes	No	10,947,244					RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA (FL) WHO HAVE RECEIVED AT LEAST THREE PRIOR LINES OF SYSTEMIC THERAPY
Tg Theraps	UKONIQ	umbralisib tosylate	TABLET;ORAL	213176-001	Feb 5, 2021		DISCN	Yes	No	9,969,740		Y	Y		RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA (FL) WHO HAVE RECEIVED AT LEAST THREE PRIOR LINES OF SYSTEMIC THERAPY
Tg Theraps	UKONIQ	umbralisib tosylate	TABLET;ORAL	213176-001	Feb 5, 2021		DISCN	Yes	No	9,969,740		Y	Y		RELAPSED OR REFRACTORY MARGINAL ZONE LYMPHOMA (MZL) WHO HAVE RECEIVED AT LEAST ONE PRIOR ANTI-CD20-BASED REGIMEN